Clinical trials: Axillary Hyperhidrosis
Axillary Hyperhidrosis
Comparison of the Clinical Efficacy and Adverse Reactions of Different Needling Patterns of High-frequency Microneedles in the Treatment of Axillary Odor
Background: Axillary osmidrosis is a common skin disease characterized by an unpleasant odor produced when secretions from apocrine sweat glands in the armpits are decomposed by bacteria on the skin.
- Trial name
- NCT07094009
- Testing
- received transverse needling, received vertical needling, received mixed needling
- Where
- China
- Volunteers
- 90 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Axillary Hyperhidrosis
Miradry Treatment for Focal Axillary Hyperhidrosis
Primary hyperhidrosis is a pathological condition characterized by the idiopathic and excessive secretion of sweat beyond normal physiological demand and is localized at particular foci such as the face, axilla, palms of the…
- Trial name
- MiraDry Tx (NCT02295891)
- Testing
- MiraDry ®
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Johns Hopkins University
Primary Axillary Hyperhidrosis
Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects with Primary Axillary Hyperhidrosis
The aim of this study is to investigate the safety, tolerability and efficacy of 1% GPB Cream compared to Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use under maximum use conditions.
- Trial name
- NCT04159610
- Testing
- WO3970, Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Axillary Hyperhidrosis
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- CardiganI (NCT03836287)
- Testing
- Sofpironium Bromide Gel, 15%, Vehicle
- Where
- 39 sites in United States
- Volunteers
- 350 people
- Sponsor
- Botanix Pharmaceuticals
Axillary Hyperhidrosis
Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- CARDIGANII (NCT03948646)
- Testing
- Sofpironium Bromide, 15%, Vehicle
- Where
- 42 sites in United States
- Volunteers
- 351 people
- Sponsor
- Botanix Pharmaceuticals
Primary Axillary Hyperhidrosis
Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyperhidrosis
The aim of this study is to evaluate the safety, tolerability and systemic exposure (in a subset of patients) of topical administration of 1% GPB in adolescents with severe primary axillary hyperhidrosis.
- Trial name
- NCT05863104
- Testing
- Glycopyrronium Bromide (GPB) Cream
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Axillary Hyperhidrosis
Patient Satisfaction and Safety of Miradry Treatment for Axillary Hyperhidrosis
Primary localized hyperhidrosis is a dermatological disorder that involves excessive sweat production without an underlying cause.
- Trial name
- NCT04546438
- Testing
- miraDry®
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Region Östergötland
Hyperhidrosis, Axillary Hyperhidrosis
miraDry Post Market Tumescent Anesthesia Study
This clinical trial will collect data on the safety and efficacy of the miraDry treatment when High Volume Anesthesia (Tumescent Anesthesia) is used as an alternate method of anesthetizing the axilla prior to the miraDry System…
- Trial name
- NCT05546710
- Testing
- miraDry treatment
- Volunteers
- healthy volunteers welcome
- Sponsor
- miraDry, Inc.
Primary Axillary Hyperhidrosis
Evaluation of N-SWEAT Patch for Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating
The Sahara Study is a study to evaluate the safety and effectiveness of the N-SWEAT Patch for use in subjects with excessive axillary sweating, or primary focal axillary hyperhidrosis.
- Trial name
- NCT04599907
- Testing
- Roll-In Cohort: Single Application of N-SWEAT Patch, Randomized Cohort: Single Application of N-SWEAT Patch
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Candesant Biomedical, Inc.
Primary Axillary Hyperhidrosis
A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- NCT03627468
- Testing
- Sofpironium Bromide Gel, 5%, Sofpironium Bromide Gel, 15%
- Where
- 12 sites in United States
- Volunteers
- 300 people
- Sponsor
- Botanix Pharmaceuticals
Primary Axillary Hyperhidrosis
Assessment of Efficacy and Safety of Topical Administration of 1% Glycopyrronium Bromide (GPB) in Patients With Primary Axillary Hyperhidrosis and the Assessment of Long-term Efficacy and Safety of Topical Administration of 1% GPB Cream in Patients With Primary Axillary Hyperhidrosis.
The aim of this study is to investigate the efficacy and safety of 1% GPB cream after 4 weeks of treatment compared with placebo with a sufficient number of patients to obtain statistically significant results, and to assess the…
- Trial name
- NCT03658616
- Testing
- WO3970
- Where
- Germany
- Volunteers
- 518 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Primary Axillary Hyperhidrosis
A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- NCT03785587
- Testing
- Sofpironium Bromide Gel, 15%
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Botanix Pharmaceuticals
Axillary Hyperhidrosis
Botox and Suction-Curettage for Treatment of Excessive Underarm Sweating (Axillary Hyperhidrosis)
The purpose of this study is to compare the effectiveness of two methods in the treatment of excessive underarm sweating (axillary hyperhidrosis): suction-curettage and Botox injections.
- Trial name
- NCT01274611
- Testing
- Botulinum Toxin Type A, Suction-Curettage
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Primary Axillary Hyperhidrosis
Fractionated Microneedle Radiofrequency for Treatment of Primary Axillary Hyperhidrosis
Twenty patients with PAH had 1 session of Fractionated microneedle radiofrequency treatment. Clinical improvement was evaluated using a Hyperhidrosis Disease Severity Scale (HDSS) and photographs were taken using the…
- Trial name
- NCT02823340
- Testing
- Fractional microneedle RF(United, Peninsula Medical, China)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xijing Hospital
Primary Axillary Hyperhidrosis
Investigation of Ascending Concentrations of Glycopyrronium Bromide (GPB) in a Topical Formulation in Subjects With Axillary Hyperhidrosis
The aim of the study is to assess the safety, tolerability, pharmacokinetics (PK) and efficacy of escalating concentrations of GPB in subjects with axillary hyperhidrosis.
- Trial name
- NCT03037788
- Testing
- WO3979, WO3970, WO3992
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Axillary Hyperhidrosis
Evaluation of the Ulthera System for Treating Axillary Hyperhidrosis
To evaluate the Ulthera System and the 7-3.0mm transducer for treating axillary hyperhidrosis.
- Trial name
- ULT-218 (NCT03320096)
- Testing
- Microfocused ultrasound with visualization
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Ulthera, Inc
Primary Axillary Hyperhidrosis
Ulthera® System for Treating Axillary Hyperhidrosis
Up to 20 enrolled subjects will be treated. Subjects will receive two Ulthera® treatments on the axillas provided 30 days apart. Follow-up visits will occur at 7, 30, 90 and 180 days following the last treatment.
- Trial name
- NCT02286765
- Testing
- Ulthera System treatment
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ulthera, Inc
Primary Axillary Hyperhidrosis
A Study of the Ulthera® System for the Treatment of Axillary Hyperhidrosis
This is a prospective, multi-center, randomized, double-blinded study. Subjects enrolled will be randomly assigned to receive either active treatments for axillary hyperhidrosis with the Ulthera System in both axillas, or sham…
- Trial name
- NCT01722461
- Testing
- Ulthera System
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- Ulthera, Inc
Primary Axillary Hyperhidrosis
Fractional Micro-Needle Radiofrequency and I Botulinum Toxin A for Primary Axillary Hyperhidrosis
Because of the limiting data about an efficacy and safety of fractional radiofrequency for the treatment of hyperhidrosis, this study aim to compare clinical efficacy by Hyperhidrosis Disease Severity Score (HDSS) between…
- Trial name
- NCT03054480
- Testing
- Fractional Micro-Needle Radiofrequency, Botulinum toxin type A
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mae Fah Luang University Hospital
Essential Axillary Hyperhidrosis
Unicentric Comparing Study of Suction Curettage With Standard BOTOX Injection in the Treatment of Patients With Essential Axillar Hyperhidrosis: Comparing of Efficacy, Duration of Effectiveness, and Adverse Events.
Part 1: patients with essential hyperhidrosis are treated one time with suction curettage in both axillae. Part 2: patients with axillary hyperhidrosis receive one treatment with suction curettage in one axilla, and at the same…
- Trial name
- NCT00669474
- Testing
- Suction curettage, Treatment with Botox
- Where
- Belgium
- Volunteers
- 25 people
- Sponsor
- University Hospital, Ghent